Latest Content

New case suggests muscarinic therapy xanomeline/trospium calms treatment‑resistant bipolar I mania with psychosis, hinting at nondopamine options.

Two psychiatrists use poetry and therapy to unpack clinician trauma, residency transformation, and how discomfort becomes a tool for patient connection.

Learn how clinicians tailor simple, measurable activity plans that boost depression and anxiety treatment—and improve long‑term adherence.

Fitbit and Google Health app data feed Amae clinicians real-time sleep, physical activity, and heart rate variability signals to spot relapse early in severe mental illness.

Clancy trial spotlights postpartum psychosis: how to recognize warning signs, emergency treatment options, and why stigma and DSM gaps hinder care.

Explore Alzheimer’s breakthroughs: lecanemab, donanemab, FDA blood tests, 2024 criteria, and new options to ease agitation and improve care.

Learn how clinicians reframe side effects, curb nocebo, and boost outcomes using expectation, open-label placebos, and conditioning in psychiatry.

Study of 470 BIPOC adults in residential care finds the Unified Treatment Model sustains reductions in eating disorder, depressive, and anxiety symptoms.

New Alzheimer trial news highlights safer anti-amyloid PMN310, cannabinoids easing agitation, tau gene therapy progress, FDA Fast Track psychosis drug, and TBI inflammation targets.

Check out the pipeline updates from July!

Learn how an experienced psychiatrist structures first visits—from chief complaint to treatment plan—using empathic listening in telehealth or in person.

Retrospective cohort study of 1305 adults finds specialized virtual behavioral health care produced clinically meaningful gambling symptom improvement within 14 days.

FDA clears first triple reuptake ADHD drug Simtriyo, offering nonstimulant relief for adults and kids 6+ with executive and emotional symptoms.